 Connection
Nancy Reau to Risk Assessment
This is a "connection" page, showing publications Nancy Reau has written about Risk Assessment.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.242 |
|
|
|
-
Reau N, Kwo PY, Rhee S, Brown RS, Agarwal K, Angus P, Gane E, Kao JH, Mantry PS, Mutimer D, Reddy KR, Tran TT, Hu YB, Gulati A, Krishnan P, Dumas EO, Porcalla A, Shulman NS, Liu W, Samanta S, Trinh R, Forns X. Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection. Hepatology. 2018 10; 68(4):1298-1307.
Score: 0.135
-
Reau N, Hamzeh FM, Lentz E, Zhou X, Jensen D. Characterization of nonrapid virologic response patients infected with HCV genotype 1 who may relapse after standard therapy with peginterferon plus ribavirin. J Viral Hepat. 2012 Feb; 19(2):94-102.
Score: 0.080
-
Sengupta S, Wroblewski K, Aronsohn A, Reau N, Reddy KG, Jensen D, Te H. Screening for Zinc Deficiency in Patients with Cirrhosis: When Should We Start? Dig Dis Sci. 2015 Oct; 60(10):3130-5.
Score: 0.027
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|